Loading...

CNTA CENTESSA PHARMACEUTICALS PLC Management Changes 8-K Filing

CNTS

CNT

CENTESSA PHARMACEUTICALS PLC

(CNTA)

2025 8-K

Fundraising Announcement

Financial Results Announcement

Product Expansion

Financial Statements

Financial Results

License Agreement

Investor Update

Financial Results

Positive Clinical Data

Financial Results

Annual General Meeting

Appointment of Chief Financ...

Financial Results Announcement

Underwriting Agreement

FDA Clears IND for Phase 1 ...

Financial Results Announcement

Investor Conferences

Investor Conferences

Data Presentation and Press...

Financial Results Announcement

Abstract Release

Financial Results and Prese...

Investor Conferences

Regulation FD Disclosure

Financial Results Announcement

Financial Results and Prese...

Sales Agreement with SVB Se...

FDA Clearance of IND Applic...

External Links:

Centessa Pharmaceuticals plc has appointed Dr. Mario Alberto Accardi as the new CEO, effective January 1, 2026, succeeding Dr. Saurabh Saha, who resigned on December 5, 2025. Dr. Accardi's salary will be $600,000 with potential bonuses and equity awards valued at $6 million.

AI Assistant

CENTESSA PHARMACEUTICALS PLC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.